Navigation Links
Microfluidic analysis of multiplex,,,PCR products for the genotyping of,,,Helicobacter pylori

f gastro-duodenal diseases, such as chronic active gastritis, peptic ulcer disease, gastric cancer, and gastric mucosa associated lymphoid tissue (MALT) lymphoma1. It is estimated that about half of the world's population is infected with H. pylori. But despite the high prevalence of infections only a minority of infected individuals will develop gastric carcinoma or MALT lymphoma. Therefore, it is essential to identify factors that might determine the possible sequelae of the H. pylori infection, such as host and environmental factors and bacterial virulence genes.
The specific H. pylori virulence genes found to be associated with possible disease outcome are the various alleles of the vacA gene, the presence of the cagA gene as a marker for a pathogenicity island, and the allelic variants of the iceA gene. The vacA gene is present in all H. pylori strains and encodes for the vacuolating cytotoxin, VacA which causes vacuolar degeneration of gastric epithelial cells. The vacA gene, although present in all strains, differs in its allelic variants in the signal region and the mid-region of the gene. The sequence variations in the signal region are distinguished into vacA s1 and vacA s2 subtypes, and the mid-region can be distinguished into m1 or m2 subtypes2. The allelic variants of the vacA gene that were detected by nested PCR were vacAs1/m1, vacAs1/m2 and vacAs2/m2. These vacA gene variants are associated with different cytotoxin activities. The cagA gene is a marker for the presence of the cag pathogenicity island, which is a 40 kb locus containing 31 genes associated with the induction of interleukin 8 secretion by gastric epithelial cells3. The allelic variants of the iceA gene are distinguished into iceA1 or iceA2 and only one of which being found in all H. pylori strains. The iceA gene seems to be induced by contact with epithelium
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. High-throughput gene expression analysis to screen for anti-asthma drugs
2. Fully automated DNA purification and efficient multiplex PCR for analysis of microsatellite loci
3. Flow cytometric analysis of human primary cells using the Agilent 2100 bioanalyzer and on-chip staining
4. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
5. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
6. High resolution DNA analysis with the DNA 500 and DNA 1000 LabChip kits
7. Extended data analysis using DeCyder EDA
8. 2D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ
9. Neurite outgrowth cell-by-cell analysis using the IN Cell Developer Toolbox
10. Laser Capture Microdissection of muscle fiber populations and expression analysis by RT-PCR
11. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
Post Your Comments:
Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Pathological gambling may be successfully treated with medications for substance addiction 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 1ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 3Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 1Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 2Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 11Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 12Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 13Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 14Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 15Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 16Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 17